What is Bio Green Med Solution Inc's earnings per share (EPS)?

Bio Green Med Solution Inc (BGMS) reported diluted earnings per share of $-6.45 for fiscal year 2025. This represents a 98.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bio Green Med Solution Inc Financials

BGMS

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Bio Green Med Solution Inc (BGMS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 28 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BGMS FY2025 2026-05-15

Bio Green Med Solution's recent numbers show a capital-funded reset: outside financing and spending cuts matter more than current sales.

FY2025's reported profit did not mark a self-funding operation: despite net income of $3.0M, the company still had an operating loss of -$8.4M. With operating cash flow at -$4.8M, the income-statement improvement did not mean the underlying business had begun paying for itself.

Even after a sharp pullback, R&D was $848K in FY2025 against just revenue of $747K, so the company is still funding development ahead of commercial scale. The bigger shift is that this spend is far below FY2023's $19.2M, which points to an activity reset rather than sales suddenly carrying the model.

The balance sheet moved from negative equity of -$2.2M in FY2024 to positive equity of $6.8M in FY2025. Since financing cash added $5.3M while operations used -$4.8M, that repair appears to have come from external capital and lower obligations, not from core operating earnings.

Financial Health Signals

Financial health score pending refresh

We are recalculating Bio Green Med Solution Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-78.05

Bio Green Med Solution Inc scores -78.05, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.1M) relative to total liabilities ($1.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Bio Green Med Solution Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

1.59x

For every $1 of reported earnings, Bio Green Med Solution Inc generates $1.59 in operating cash flow (-$4.8M OCF vs -$3.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-135.9x

Bio Green Med Solution Inc earns $-135.9 in operating income for every $1 of interest expense (-$8.4M vs $62K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$747K

YoY+1637.2%

10Y CAGR-9.1%

Bio Green Med Solution Inc generated $747K in revenue in fiscal year 2025. This represents an increase of 1637.2% from the prior year.

EBITDA

-$8.4M

YoY+29.8%

Bio Green Med Solution Inc's EBITDA was -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 29.8% from the prior year.

Net Income

-$3.0M

YoY+73.3%

Bio Green Med Solution Inc reported -$3.0M in net income in fiscal year 2025. This represents an increase of 73.3% from the prior year.

EPS (Diluted)

$-6.45

YoY+98.7%

Bio Green Med Solution Inc earned $-6.45 per diluted share (EPS) in fiscal year 2025. This represents an increase of 98.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3.5M

YoY+11.7%

5Y CAGR-36.3%

10Y CAGR-16.2%

Bio Green Med Solution Inc held $3.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+14529.9%

Bio Green Med Solution Inc had 5M shares outstanding in fiscal year 2025. This represents an increase of 14529.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-1128.1%

YoY+26788.2pp

10Y CAGR-296.3pp

Bio Green Med Solution Inc's operating margin was -1128.1% in fiscal year 2025, reflecting core business profitability. This is up 26788.2 percentage points from the prior year.

Net Margin

-401.3%

YoY+25673.1pp

10Y CAGR+336.4pp

Bio Green Med Solution Inc's net profit margin was -401.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 25673.1 percentage points from the prior year.

Return on Equity

-43.8%

5Y CAGR-18.4pp

10Y CAGR+32.3pp

Bio Green Med Solution Inc's ROE was -43.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$848K

YoY-87.3%

5Y CAGR-29.2%

10Y CAGR-23.5%

Bio Green Med Solution Inc invested $848K in research and development in fiscal year 2025. This represents a decrease of 87.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BGMS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$747K+1637.2%	$43K-89.8%	$420K	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$848K-87.3%	$6.7M-65.3%	$19.2M-5.5%	$20.3M+35.8%	$14.9M+213.7%	$4.8M
SG&A Expenses	$7.7M+43.1%	$5.4M-19.7%	$6.7M-9.0%	$7.4M-1.1%	$7.5M+27.0%	$5.9M
Operating Income	-$8.4M+29.8%	-$12.0M+52.8%	-$25.5M+8.0%	-$27.7M-23.5%	-$22.4M-110.5%	-$10.6M
Interest Expense	$62K+416.7%	$12K	N/A	N/A	N/A	N/A
Income Tax	$7K+100.9%	-$782K+73.9%	-$3.0M+36.5%	-$4.7M-26.5%	-$3.7M-201.6%	-$1.2M
Net Income	-$3.0M+73.3%	-$11.2M-149.7%	$22.6M+206.4%	-$21.2M-14.9%	-$18.5M-118.6%	-$8.4M
EPS (Diluted)	$-6.45+98.7%	$-502.46-7727.5%	$-6.42	$-27.24	$-2.09+38.9%	$-3.42

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$743K	N/A	$81K	N/A	N/A	$0-100.0%	$10K+150.0%	$4K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	$5K-92.6%	$68K-91.7%	$822K-6.6%	$880K-7.4%	$950K-53.0%	$2.0M
SG&A Expenses	$389K	N/A	$1.0M-19.6%	$1.2M-70.4%	$4.2M+344.5%	$948K-23.4%	$1.2M-23.9%	$1.6M
Operating Income	-$246K	N/A	-$992K+24.7%	-$1.3M+68.7%	-$4.2M-130.5%	-$1.8M+16.0%	-$2.2M+40.3%	-$3.6M
Interest Expense	$9K	N/A	$9K+350.0%	$2K-66.7%	$6K-80.0%	$30K+275.0%	$8K+128.6%	-$28K
Income Tax	$30K	N/A	N/A	$2K	N/A	$1.2M+668.6%	-$210K+49.0%	-$412K
Net Income	-$197K	N/A	-$988K+25.0%	-$1.3M-1527.2%	-$81K+97.3%	-$3.1M-56.0%	-$2.0M+39.9%	-$3.3M
EPS (Diluted)	$-0.04	N/A	$-1.31-33.7%	$-0.98	$0.00	N/A	$-43.80	$-172.18

BGMS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.2M+99.9%	$4.1M-53.5%	$8.8M-68.6%	$28.1M-35.0%	$43.1M+17.2%	$36.8M
Current Assets	$6.3M+70.3%	$3.7M-50.6%	$7.4M-69.5%	$24.4M-40.4%	$40.9M+15.4%	$35.5M
Cash & Equivalents	$3.5M+11.7%	$3.1M-7.1%	$3.4M-81.6%	$18.3M-49.8%	$36.6M+9.4%	$33.4M
Inventory	$1.4M	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.3M	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.6M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3M-78.6%	$6.3M-23.5%	$8.2M+7.6%	$7.6M+39.9%	$5.4M+53.6%	$3.5M
Current Liabilities	$1.3M-78.7%	$6.3M-23.2%	$8.2M+8.7%	$7.5M+38.8%	$5.4M+117.7%	$2.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.8M+414.7%	-$2.2M-458.2%	$607K-96.2%	$15.9M-57.7%	$37.7M+13.3%	$33.3M
Retained Earnings	-$454.4M-3.4%	-$439.5M-2.6%	-$428.3M-5.6%	-$405.7M-5.5%	-$384.5M-5.0%	-$366.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$7.6M-7.6%	$8.2M+0.3%	$8.2M+85.4%	$4.4M+17.9%	$3.7M-8.8%	$4.1M-23.9%	$5.4M-34.3%	$8.2M
Current Assets	$5.6M-10.1%	$6.3M-2.9%	$6.4M+47.0%	$4.4M+18.0%	$3.7M+1.1%	$3.7M-25.2%	$4.9M-36.3%	$7.7M
Cash & Equivalents	$3.3M-4.7%	$3.5M-8.7%	$3.8M-10.2%	$4.3M+23.9%	$3.5M+10.0%	$3.1M+5.2%	$3.0M-50.3%	$6.0M
Inventory	$947K-31.6%	$1.4M+1.2%	$1.4M	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.2M-5.5%	$1.3M+73.4%	$725K	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.6M0.0%	$1.6M0.0%	$1.6M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$804K-40.1%	$1.3M+26.5%	$1.1M+37.9%	$770K+14.6%	$672K-89.3%	$6.3M-1.3%	$6.4M-11.7%	$7.2M
Current Liabilities	$796K-40.2%	$1.3M+32.9%	$1.0M+31.8%	$760K+14.6%	$663K-89.4%	$6.3M-1.3%	$6.4M-11.6%	$7.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.8M-1.2%	$6.8M-3.6%	$7.1M+95.4%	$3.6M+18.6%	$3.1M+240.8%	-$2.2M-124.1%	-$970K-197.1%	$999K
Retained Earnings	-$454.6M0.0%	-$454.4M-2.3%	-$444.3M-0.6%	-$441.8M-0.3%	-$440.5M-0.2%	-$439.5M-0.7%	-$436.4M-0.5%	-$434.5M

BGMS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$4.8M+40.3%	-$8.0M+50.4%	-$16.1M+22.6%	-$20.8M-12.3%	-$18.5M-133.7%	-$7.9M
Capital Expenditures	N/A	N/A	$6K-14.3%	$7K-74.1%	$27K-71.9%	$96K
Free Cash Flow	N/A	N/A	-$16.1M+22.6%	-$20.8M-12.2%	-$18.6M-131.2%	-$8.0M
Investing Cash Flow	N/A	N/A	-$6K+14.3%	-$7K+74.1%	-$27K+71.9%	-$96K
Financing Cash Flow	$5.3M-32.7%	$7.8M+822.4%	$848K-71.7%	$3.0M-86.2%	$21.7M-26.3%	$29.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$278K-742.4%	-$33K+92.4%	-$434K+58.9%	-$1.1M+67.5%	-$3.2M-139.5%	-$1.4M+55.8%	-$3.1M+0.6%	-$3.1M
Capital Expenditures	$1K	N/A	N/A	N/A	N/A	N/A	$0	N/A
Free Cash Flow	-$279K	N/A	N/A	N/A	N/A	N/A	-$3.1M	N/A
Investing Cash Flow	-$1K	N/A	N/A	N/A	N/A	N/A	$0	N/A
Financing Cash Flow	$105K+140.5%	-$259K-8533.3%	-$3K-100.2%	$1.9M-48.4%	$3.6M+126.0%	$1.6M+161400.0%	-$1K-100.0%	$6.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BGMS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1128.1%+26788.2pp	-27916.3%-21856.0pp	-6060.2%	N/A	N/A	N/A
Net Margin	-401.3%+25673.1pp	-26074.4%-31444.7pp	5370.2%	N/A	N/A	N/A
Return on Equity	-43.8%	N/A	3715.8%+3848.8pp	-133.0%-84.0pp	-49.0%-23.6pp	-25.4%
Return on Assets	-36.6%+237.2pp	-273.9%-530.0pp	256.2%+331.7pp	-75.6%-32.8pp	-42.8%-19.8pp	-22.9%
Current Ratio	4.70+4.1	0.59-0.3	0.91-2.3	3.25-4.3	7.56-6.7	14.27
Debt-to-Equity	0.20	N/A	13.51+13.0	0.48+0.3	0.14+0.0	0.11
FCF Margin	N/A	N/A	-3837.6%	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-33.1%	N/A	-1224.7%	N/A	N/A	N/A	-21770.0%+69330.0pp	-91100.0%
Net Margin	-26.5%	N/A	-1219.8%	N/A	N/A	N/A	-19570.0%+61855.0pp	-81425.0%
Return on Equity	-2.9%	N/A	-13.9%+22.4pp	-36.3%-33.6pp	-2.6%	N/A	N/A	-326.0%
Return on Assets	-2.6%	N/A	-12.1%+17.8pp	-29.9%-27.8pp	-2.2%+72.4pp	-74.6%-38.2pp	-36.4%+3.4pp	-39.8%
Current Ratio	7.06+2.4	4.70-1.7	6.43+0.7	5.77+0.2	5.60+5.0	0.59-0.2	0.77-0.3	1.07
Debt-to-Equity	0.12-0.1	0.20+0.0	0.15-0.1	0.210.0	0.22	N/A	N/A	7.20
FCF Margin	-37.5%	N/A	N/A	N/A	N/A	N/A	-30670.0%	N/A

Frequently Asked Questions

What is Bio Green Med Solution Inc's annual revenue?

Bio Green Med Solution Inc (BGMS) reported $747K in total revenue for fiscal year 2025. This represents a 1637.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bio Green Med Solution Inc's revenue growing?

Bio Green Med Solution Inc (BGMS) revenue grew by 1637.2% year-over-year, from $43K to $747K in fiscal year 2025.

Is Bio Green Med Solution Inc profitable?

No, Bio Green Med Solution Inc (BGMS) reported a net income of -$3.0M in fiscal year 2025, with a net profit margin of -401.3%.

What is Bio Green Med Solution Inc's EBITDA?

Bio Green Med Solution Inc (BGMS) had EBITDA of -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Bio Green Med Solution Inc's operating margin?

Bio Green Med Solution Inc (BGMS) had an operating margin of -1128.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bio Green Med Solution Inc's net profit margin?

Bio Green Med Solution Inc (BGMS) had a net profit margin of -401.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bio Green Med Solution Inc's return on equity (ROE)?

Bio Green Med Solution Inc (BGMS) has a return on equity of -43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bio Green Med Solution Inc's operating cash flow?

Bio Green Med Solution Inc (BGMS) generated -$4.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bio Green Med Solution Inc's total assets?

Bio Green Med Solution Inc (BGMS) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Bio Green Med Solution Inc spend on research and development?

Bio Green Med Solution Inc (BGMS) invested $848K in research and development during fiscal year 2025.

How many shares does Bio Green Med Solution Inc have outstanding?

Bio Green Med Solution Inc (BGMS) had 5M shares outstanding as of fiscal year 2025.

What is Bio Green Med Solution Inc's current ratio?

Bio Green Med Solution Inc (BGMS) had a current ratio of 4.70 as of fiscal year 2025, which is generally considered healthy.

What is Bio Green Med Solution Inc's debt-to-equity ratio?

Bio Green Med Solution Inc (BGMS) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bio Green Med Solution Inc's return on assets (ROA)?

Bio Green Med Solution Inc (BGMS) had a return on assets of -36.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bio Green Med Solution Inc's cash runway?

Based on fiscal year 2025 data, Bio Green Med Solution Inc (BGMS) had $3.5M in cash against an annual operating cash burn of $4.8M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bio Green Med Solution Inc's Altman Z-Score?

Bio Green Med Solution Inc (BGMS) has an Altman Z-Score of -78.05, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Bio Green Med Solution Inc's Piotroski F-Score?

Bio Green Med Solution Inc (BGMS) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bio Green Med Solution Inc's earnings high quality?

Bio Green Med Solution Inc (BGMS) has an earnings quality ratio of 1.59x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bio Green Med Solution Inc cover its interest payments?

Bio Green Med Solution Inc (BGMS) has an interest coverage ratio of -135.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.